Skip to content

Study · Case report or series · n = 1 · 2026

1 result

Investigating the Link Between Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Non-arteritic Ischemic Optic Neuropathy: A Case Report of Semaglutide-Induced Optic Neuropathy.

Bakheet M, Chaudhary A

Cureus28 Jan 2026

PMID41769577 (opens in a new tab)PMCIDPMC12947803 (opens in a new tab)DOI10.7759/cureus.102472 (opens in a new tab)PepBankPUB-41769577
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are newer medications used to treat type 2 diabetes mellitus (T2DM) and obesity. There is growing evidence of a potential association between the use of GLP-1 RAs and non-arteritic anterior ischemic optic neuropathy (NAION). Here, we report a case of NAION in a young patient with diabetes receiving semaglutide (GLP-1 RA), which showed a complete resolution of symptoms after discontinuing the GLP-1 RA. This case adds to growing concerns, given emerging evidence suggesting an increased incidence of NAION among users of GLP-1 RAs. Further studies are required to clarify causality, identify risk factors, and develop monitoring strategies for patients receiving GLP-1 RAs.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In one young patient with diabetes receiving semaglutide, non-arteritic anterior ischemic optic neuropathy occurred and symptoms resolved completely after the drug was stopped.

    In plain wordsOne young patient with diabetes on semaglutide had an optic nerve problem that went away after stopping the drug. One case cannot show cause.

    Peptide
    Semaglutide
    Outcome
    Not applicableNon-arteritic anterior ischemic optic neuropathy (NAION)
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here, we report a case of NAION in a young patient with diabetes receiving semaglutide (GLP-1 RA), which showed a complete resolution of symptoms after discontinuing the GLP-1 RA.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.